The cookie settings on this website are set to 'allow all cookies' to give you the very best experience. Please click Accept Cookies to continue to use the site.

NEW Soluble Leptin Receptor (sLEP-R) ELISA

Aug 29th 2019

We are pleased to announce the release of the new Soluble Leptin Receptor (sLEP-R) ELISA suitable for serum or plasma.

The adipokine leptin realizes signal transduction via four different leptin receptor (LEP-R) isoforms. The amount of functionally active LEP-R, however, is affected by constitutive shedding of the extracellular domain. The product of the cleavage process, the so-called soluble leptin receptor (sLEP-R, soluble Leptin receptor), is the main binding protein for leptin in human blood and modulates its bioavailability.

Concentrations of sLEP-R are differentially regulated in metabolic disorders, such as type 1 diabetes mellitus or obesity and can therefore enhance or reduce leptin sensitivity.

Lipotoxicity and apoptosis increase LEP-R cleavage via ADAM10-dependent mechanisms. 

In contrast, although increased sLEP-R concentrations seem directly to inhibit leptin effects, reduced amounts of sLEP-R may reflect decreased membrane expression of LEP-R. These findings, in part, explain alterations of leptin sensitivity that are associated with changes in serum sLEP-R concentrations seen in metabolic disorders.

Click here for package insert.

Product overview:

Catalog Number R07
Controls 2 controls, lyophilized
Sample Types Serum or plasma
Sample Volume 30 µL single determination / 50 µL double determination
Standards 8 standards, lyophilized
Standard Range 0 / 3.125 - 150 ng/mL
Sensitivity 0.0385 ng/mL
Incubation Time 5 hours total incubation time
FDA Status Research Use Only